Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-02

AUTHORS

Joyce O’Shaughnessy, Katarina Petrakova, Gabe S. Sonke, Pierfranco Conte, Carlos L. Arteaga, David A. Cameron, Lowell L. Hart, Cristian Villanueva, Erik Jakobsen, Joseph T. Beck, Deborah Lindquist, Farida Souami, Shoubhik Mondal, Caroline Germa, Gabriel N. Hortobagyi

ABSTRACT

PURPOSE: Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. METHODS: Postmenopausal women with HR+ , HER2- advanced breast cancer and no prior systemic therapy for advanced disease were enrolled in the Phase III MONALEESA-2 trial (NCT01958021). Patients were randomized to ribociclib (600 mg/day; 3 weeks-on/1 week-off) plus letrozole (2.5 mg/day; continuous) or placebo plus letrozole until disease progression, unacceptable toxicity, death, or treatment discontinuation. The primary endpoint was investigator-assessed progression-free survival; predefined subgroup analysis evaluated progression-free survival in patients with de novo advanced breast cancer. Secondary endpoints included safety and overall response rate. RESULTS: Six hundred and sixty-eight patients were enrolled, of whom 227 patients (34%; ribociclib plus letrozole vs placebo plus letrozole arm: n = 114 vs. n = 113) presented with de novo advanced breast cancer. Median progression-free survival was not reached in the ribociclib plus letrozole arm versus 16.4 months in the placebo plus letrozole arm in patients with de novo advanced breast cancer (hazard ratio 0.45, 95% confidence interval 0.27-0.75). The most common Grade 3/4 adverse events were neutropenia and leukopenia; incidence rates were similar to those observed in the full MONALEESA-2 population. Ribociclib dose interruptions and reductions in patients with de novo disease occurred at similar frequencies to the overall study population. CONCLUSIONS: Ribociclib plus letrozole improved progression-free survival vs placebo plus letrozole and was well tolerated in postmenopausal women with HR+, HER2- de novo advanced breast cancer. More... »

PAGES

127-134

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-017-4518-8

DOI

http://dx.doi.org/10.1007/s10549-017-4518-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1092841000

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29164421


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aminopyridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Combined Chemotherapy Protocols", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy-Induced Febrile Neutropenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Incidence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Letrozole", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leukopenia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postmenopause", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Progression-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Purines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Estrogen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Progesterone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Response Evaluation Criteria in Solid Tumors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Texas Oncology", 
          "id": "https://www.grid.ac/institutes/grid.477898.d", 
          "name": [
            "Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, 3410 Worth Street, Suite 400, 75246, Dallas, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "O\u2019Shaughnessy", 
        "givenName": "Joyce", 
        "id": "sg:person.0612217745.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612217745.26"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Masaryk Memorial Cancer Institute", 
          "id": "https://www.grid.ac/institutes/grid.419466.8", 
          "name": [
            "Masaryk Memorial Cancer Institute, \u017dlut\u00fd kopec 543/7, 656 53, Brno, Czech Republic"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Petrakova", 
        "givenName": "Katarina", 
        "id": "sg:person.01000127754.79", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000127754.79"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Antoni van Leeuwenhoek Hospital", 
          "id": "https://www.grid.ac/institutes/grid.430814.a", 
          "name": [
            "Netherlands Cancer Institute and BOOG Study Center, IJsbaanpad 9, 1076 CV, Amsterdam, The Netherlands"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sonke", 
        "givenName": "Gabe S.", 
        "id": "sg:person.0761732367.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761732367.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Istituti di Ricovero e Cura a Carattere Scientifico", 
          "id": "https://www.grid.ac/institutes/grid.414603.4", 
          "name": [
            "University of Padova and Istituto Oncologico Veneto, IRCCS, Via Gattamelata, 64, Padua, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Conte", 
        "givenName": "Pierfranco", 
        "id": "sg:person.0646473315.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646473315.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vanderbilt University Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.412807.8", 
          "name": [
            "Vanderbilt-Ingram Cancer Center, 1301 Medical Center Dr #1710, 37232, Nashville, TN, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Arteaga", 
        "givenName": "Carlos L.", 
        "id": "sg:person.013436233237.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013436233237.01"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Edinburgh", 
          "id": "https://www.grid.ac/institutes/grid.4305.2", 
          "name": [
            "Edinburgh Cancer Centre, University of Edinburgh, Crewe Rd S, EH4 2XR, Edinburgh, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cameron", 
        "givenName": "David A.", 
        "id": "sg:person.01215373156.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215373156.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Sarah Cannon Research Institute, 33916, Fort Myers, FL, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hart", 
        "givenName": "Lowell L.", 
        "id": "sg:person.01024444431.61", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024444431.61"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Besan\u00e7on", 
          "id": "https://www.grid.ac/institutes/grid.411158.8", 
          "name": [
            "University Hospital of Besan\u00e7on, Jean-Minjoz University Hospital, 3 Boulevard Alexandre Fleming, 25000, Besan\u00e7on, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Villanueva", 
        "givenName": "Cristian", 
        "id": "sg:person.0756327401.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756327401.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Sygehus Lilleb\u00e6lt", 
          "id": "https://www.grid.ac/institutes/grid.459623.f", 
          "name": [
            "Lillebaelt Hospital, Kabbeltoft 25, 7100, Vejle, Denmark"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jakobsen", 
        "givenName": "Erik", 
        "id": "sg:person.0632337317.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632337317.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Highlands Oncology Group", 
          "id": "https://www.grid.ac/institutes/grid.492660.f", 
          "name": [
            "Highlands Oncology Group, 3232 N Northhills Blvd, 72703, Fayetteville, AR, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Beck", 
        "givenName": "Joseph T.", 
        "id": "sg:person.01304125215.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304125215.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Arizona Oncology", 
          "id": "https://www.grid.ac/institutes/grid.492893.d", 
          "name": [
            "Arizona Oncology, US Oncology Network, 3700 W State Rte 89A, 86336, Sedona, AZ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lindquist", 
        "givenName": "Deborah", 
        "id": "sg:person.01237201171.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237201171.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Souami", 
        "givenName": "Farida", 
        "id": "sg:person.01035671320.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035671320.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, 1 Health Plaza, 07936, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mondal", 
        "givenName": "Shoubhik", 
        "id": "sg:person.07527031577.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07527031577.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, 1 Health Plaza, 07936, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Germa", 
        "givenName": "Caroline", 
        "id": "sg:person.0774357225.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774357225.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas MD Anderson Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.240145.6", 
          "name": [
            "University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hortobagyi", 
        "givenName": "Gabriel N.", 
        "id": "sg:person.01365732165.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365732165.24"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1056/nejmoa1607303", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005496514"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2016.67.1487", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010471013"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(16)32619-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010989294"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3322/caac.21254", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011682275"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(16)32389-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014303949"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-014-2916-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017207411", 
          "https://doi.org/10.1007/s10549-014-2916-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10549-014-2916-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017207411", 
          "https://doi.org/10.1007/s10549-014-2916-8"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrd4504", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021914398", 
          "https://doi.org/10.1038/nrd4504"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature11412", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1024942368", 
          "https://doi.org/10.1038/nature11412"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00613-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025211268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00613-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025211268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00613-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025211268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(15)00613-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025211268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2008.10.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026558254"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1530/erc-10-0262", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031547310"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdq220", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037043739"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1371/journal.pone.0093755", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038929656"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.breast.2016.05.015", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042721440"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2147/pgpm.s52762", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1044821228"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1609709", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045557388"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.breast.2016.10.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046767167"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2015.127", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050007381", 
          "https://doi.org/10.1038/bjc.2015.127"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1535-7163.targ-13-pr02", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063229039"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw435.05", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083560034"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw544", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083734065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2017.73.7585", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085860547"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092559985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx447", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092559985"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-02", 
    "datePublishedReg": "2018-02-01", 
    "description": "PURPOSE: Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer.\nMETHODS: Postmenopausal women with HR+\u00a0, HER2- advanced breast cancer and no prior systemic therapy for advanced disease were enrolled in the Phase III MONALEESA-2 trial (NCT01958021). Patients were randomized to ribociclib (600\u00a0mg/day; 3\u00a0weeks-on/1\u00a0week-off) plus letrozole (2.5\u00a0mg/day; continuous) or placebo plus letrozole until disease progression, unacceptable toxicity, death, or treatment discontinuation. The primary endpoint was investigator-assessed progression-free survival; predefined subgroup analysis evaluated progression-free survival in patients with de novo advanced breast cancer. Secondary endpoints included safety and overall response rate.\nRESULTS: Six hundred and sixty-eight patients were enrolled, of whom 227 patients (34%; ribociclib plus letrozole vs placebo plus letrozole arm: n\u00a0=\u00a0114 vs. n\u00a0=\u00a0113) presented with de novo advanced breast cancer. Median progression-free survival was not reached in the ribociclib plus letrozole arm versus 16.4\u00a0months in the placebo plus letrozole arm in patients with de novo advanced breast cancer (hazard ratio 0.45, 95% confidence interval 0.27-0.75). The most common Grade 3/4 adverse events were neutropenia and leukopenia; incidence rates were similar to those observed in the full MONALEESA-2 population. Ribociclib dose interruptions and reductions in patients with de novo disease occurred at similar frequencies to the overall study population.\nCONCLUSIONS: Ribociclib plus letrozole improved progression-free survival vs placebo plus letrozole and was well tolerated in postmenopausal women with HR+, HER2- de novo advanced breast cancer.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10549-017-4518-8", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "168"
      }
    ], 
    "name": "Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2\u2212 advanced breast cancer in the randomized MONALEESA-2 trial", 
    "pagination": "127-134", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "16ba3df87594e03832591ae3b7816b983a2627b6cac92786d849da1536a34c84"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29164421"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-017-4518-8"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1092841000"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-017-4518-8", 
      "https://app.dimensions.ai/details/publication/pub.1092841000"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:27", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000362_0000000362/records_87115_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10549-017-4518-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-017-4518-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-017-4518-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-017-4518-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-017-4518-8'


 

This table displays all metadata directly associated to this object as RDF triples.

366 TRIPLES      21 PREDICATES      74 URIs      43 LITERALS      31 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-017-4518-8 schema:about N04b85196c33c422f8d724b7251f9265a
2 N05051330f21145b9bba2841ba8e5a9aa
3 N086ddde98afc469eb9e7676499bebd06
4 N1c28d18d39db46b19d16f1f9885bc2f8
5 N1f8d341f4fdd4ea1bb1bdc14367222f7
6 N24187058043f4f61b1285ec539fa71a2
7 N29e0599f9c224b06b7d7fecbf9a7b10d
8 N3388eebeef53491ba111462c4247adb4
9 N6e5c6160ebc044e48edf4dbb74925d5f
10 N7210ec29db6a4dadb56aaf3d3dd6e680
11 N8bcedb9ff3a242ffb2eb91af0ade5260
12 N8d98380ba2f247a5ad0fa563c6ea9210
13 N8f7b98bad54e41bbbbb184a1712a51bd
14 N9ec0b4d1868c40ef96e44a9efd51025d
15 Na6c4a70a1515441c873b27705905a98b
16 Na7faa472a0f849a486f0ccd422639d38
17 Na8144feb8d054cfe9a41ff1671fadd1b
18 Nb610bcbf795044d9b15e6f62325053f3
19 Nb863322e77f947f08bdfecf27e086124
20 Nc02dfece5e9e4089b4d474f4a3f0c8d9
21 Ndc6fbce647f04bcfbb664dacd058755c
22 Nfe527efe4c344df7883057e65f981690
23 anzsrc-for:11
24 anzsrc-for:1112
25 schema:author N388fd37fa3ce4b6eacc8c92991827791
26 schema:citation sg:pub.10.1007/s10549-014-2916-8
27 sg:pub.10.1038/bjc.2015.127
28 sg:pub.10.1038/nature11412
29 sg:pub.10.1038/nrd4504
30 https://doi.org/10.1016/j.breast.2016.05.015
31 https://doi.org/10.1016/j.breast.2016.10.001
32 https://doi.org/10.1016/j.ejca.2008.10.026
33 https://doi.org/10.1016/s0140-6736(16)32389-3
34 https://doi.org/10.1016/s0959-8049(16)32619-3
35 https://doi.org/10.1016/s1470-2045(15)00613-0
36 https://doi.org/10.1056/nejmoa1607303
37 https://doi.org/10.1056/nejmoa1609709
38 https://doi.org/10.1093/annonc/mdq220
39 https://doi.org/10.1093/annonc/mdw435.05
40 https://doi.org/10.1093/annonc/mdw544
41 https://doi.org/10.1093/annonc/mdx447
42 https://doi.org/10.1158/1535-7163.targ-13-pr02
43 https://doi.org/10.1200/jco.2016.67.1487
44 https://doi.org/10.1200/jco.2017.73.7585
45 https://doi.org/10.1371/journal.pone.0093755
46 https://doi.org/10.1530/erc-10-0262
47 https://doi.org/10.2147/pgpm.s52762
48 https://doi.org/10.3322/caac.21254
49 schema:datePublished 2018-02
50 schema:datePublishedReg 2018-02-01
51 schema:description PURPOSE: Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. METHODS: Postmenopausal women with HR+ , HER2- advanced breast cancer and no prior systemic therapy for advanced disease were enrolled in the Phase III MONALEESA-2 trial (NCT01958021). Patients were randomized to ribociclib (600 mg/day; 3 weeks-on/1 week-off) plus letrozole (2.5 mg/day; continuous) or placebo plus letrozole until disease progression, unacceptable toxicity, death, or treatment discontinuation. The primary endpoint was investigator-assessed progression-free survival; predefined subgroup analysis evaluated progression-free survival in patients with de novo advanced breast cancer. Secondary endpoints included safety and overall response rate. RESULTS: Six hundred and sixty-eight patients were enrolled, of whom 227 patients (34%; ribociclib plus letrozole vs placebo plus letrozole arm: n = 114 vs. n = 113) presented with de novo advanced breast cancer. Median progression-free survival was not reached in the ribociclib plus letrozole arm versus 16.4 months in the placebo plus letrozole arm in patients with de novo advanced breast cancer (hazard ratio 0.45, 95% confidence interval 0.27-0.75). The most common Grade 3/4 adverse events were neutropenia and leukopenia; incidence rates were similar to those observed in the full MONALEESA-2 population. Ribociclib dose interruptions and reductions in patients with de novo disease occurred at similar frequencies to the overall study population. CONCLUSIONS: Ribociclib plus letrozole improved progression-free survival vs placebo plus letrozole and was well tolerated in postmenopausal women with HR+, HER2- de novo advanced breast cancer.
52 schema:genre research_article
53 schema:inLanguage en
54 schema:isAccessibleForFree true
55 schema:isPartOf N7a7c80ff3afd4209aa05cb84f79a5a2c
56 Nb6edcd235b0246eb84ebcdf558486bc0
57 sg:journal.1092777
58 schema:name Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial
59 schema:pagination 127-134
60 schema:productId N094b038ba3774b9a9c8ea85bdb914737
61 N2a7e6c9cade24daaa7a34ee03f2ac225
62 N5bfbae8744bf47efa81e1fbf1b98672a
63 Nec7bf1777ec648fba105324205d8ea58
64 Nf83546db11984b31bf664bfd91f4b55c
65 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092841000
66 https://doi.org/10.1007/s10549-017-4518-8
67 schema:sdDatePublished 2019-04-11T12:27
68 schema:sdLicense https://scigraph.springernature.com/explorer/license/
69 schema:sdPublisher N90064b2559bf4da4867998ef88e5ece7
70 schema:url https://link.springer.com/10.1007%2Fs10549-017-4518-8
71 sgo:license sg:explorer/license/
72 sgo:sdDataset articles
73 rdf:type schema:ScholarlyArticle
74 N005455949be846c18f7b57d1b5ed76c3 schema:name Sarah Cannon Research Institute, 33916, Fort Myers, FL, USA
75 rdf:type schema:Organization
76 N04b85196c33c422f8d724b7251f9265a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
77 schema:name Response Evaluation Criteria in Solid Tumors
78 rdf:type schema:DefinedTerm
79 N05051330f21145b9bba2841ba8e5a9aa schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Adult
81 rdf:type schema:DefinedTerm
82 N086ddde98afc469eb9e7676499bebd06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Breast Neoplasms
84 rdf:type schema:DefinedTerm
85 N09218f909a314d6da8b96c86fe7847b9 rdf:first sg:person.0756327401.00
86 rdf:rest Na2554654c35548238be937b7583c1236
87 N094b038ba3774b9a9c8ea85bdb914737 schema:name dimensions_id
88 schema:value pub.1092841000
89 rdf:type schema:PropertyValue
90 N09af62adb7ea44469dced71c2c904d17 rdf:first sg:person.01365732165.24
91 rdf:rest rdf:nil
92 N1c28d18d39db46b19d16f1f9885bc2f8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
93 schema:name Kaplan-Meier Estimate
94 rdf:type schema:DefinedTerm
95 N1f8d341f4fdd4ea1bb1bdc14367222f7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
96 schema:name Incidence
97 rdf:type schema:DefinedTerm
98 N24187058043f4f61b1285ec539fa71a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Female
100 rdf:type schema:DefinedTerm
101 N29e0599f9c224b06b7d7fecbf9a7b10d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Leukopenia
103 rdf:type schema:DefinedTerm
104 N2a7e6c9cade24daaa7a34ee03f2ac225 schema:name readcube_id
105 schema:value 16ba3df87594e03832591ae3b7816b983a2627b6cac92786d849da1536a34c84
106 rdf:type schema:PropertyValue
107 N3388eebeef53491ba111462c4247adb4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Time Factors
109 rdf:type schema:DefinedTerm
110 N388fd37fa3ce4b6eacc8c92991827791 rdf:first sg:person.0612217745.26
111 rdf:rest N953f43a455644a36b5d89facdcf91762
112 N43f40f8213e74ba0a55f7bce454be670 rdf:first sg:person.013436233237.01
113 rdf:rest Nb0c9e1d03eab461ab2a399f6c650120e
114 N5bfbae8744bf47efa81e1fbf1b98672a schema:name doi
115 schema:value 10.1007/s10549-017-4518-8
116 rdf:type schema:PropertyValue
117 N6426d588212a4061b210d78ddef9efd3 rdf:first sg:person.01237201171.19
118 rdf:rest Nb96fb577d9f04e92b41d289e04afb942
119 N6e5c6160ebc044e48edf4dbb74925d5f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Receptors, Progesterone
121 rdf:type schema:DefinedTerm
122 N7210ec29db6a4dadb56aaf3d3dd6e680 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Breast
124 rdf:type schema:DefinedTerm
125 N7a7c80ff3afd4209aa05cb84f79a5a2c schema:volumeNumber 168
126 rdf:type schema:PublicationVolume
127 N8bcedb9ff3a242ffb2eb91af0ade5260 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Aged, 80 and over
129 rdf:type schema:DefinedTerm
130 N8d98380ba2f247a5ad0fa563c6ea9210 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Chemotherapy-Induced Febrile Neutropenia
132 rdf:type schema:DefinedTerm
133 N8f7b98bad54e41bbbbb184a1712a51bd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
134 schema:name Progression-Free Survival
135 rdf:type schema:DefinedTerm
136 N90064b2559bf4da4867998ef88e5ece7 schema:name Springer Nature - SN SciGraph project
137 rdf:type schema:Organization
138 N94c13bd055a1447fadd8f7ffccfc2862 rdf:first sg:person.01024444431.61
139 rdf:rest N09218f909a314d6da8b96c86fe7847b9
140 N9506ea2802cc4a89aaa1de0002d0f01d rdf:first sg:person.07527031577.24
141 rdf:rest Nfc2aaf2c54714d779f2a8a101fc18050
142 N953f43a455644a36b5d89facdcf91762 rdf:first sg:person.01000127754.79
143 rdf:rest Nc83257e201194669b0ae12a96dd6cf6e
144 N9ec0b4d1868c40ef96e44a9efd51025d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
145 schema:name Humans
146 rdf:type schema:DefinedTerm
147 Na2554654c35548238be937b7583c1236 rdf:first sg:person.0632337317.47
148 rdf:rest Nfcc6cbb5cd1e4d7dbd9505becb7273c1
149 Na4ffbd486ac64784982d9c4046d81eee rdf:first sg:person.0646473315.72
150 rdf:rest N43f40f8213e74ba0a55f7bce454be670
151 Na6c4a70a1515441c873b27705905a98b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Postmenopause
153 rdf:type schema:DefinedTerm
154 Na7faa472a0f849a486f0ccd422639d38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Purines
156 rdf:type schema:DefinedTerm
157 Na8144feb8d054cfe9a41ff1671fadd1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Aminopyridines
159 rdf:type schema:DefinedTerm
160 Nb0c9e1d03eab461ab2a399f6c650120e rdf:first sg:person.01215373156.15
161 rdf:rest N94c13bd055a1447fadd8f7ffccfc2862
162 Nb610bcbf795044d9b15e6f62325053f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
163 schema:name Letrozole
164 rdf:type schema:DefinedTerm
165 Nb6edcd235b0246eb84ebcdf558486bc0 schema:issueNumber 1
166 rdf:type schema:PublicationIssue
167 Nb863322e77f947f08bdfecf27e086124 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Antineoplastic Combined Chemotherapy Protocols
169 rdf:type schema:DefinedTerm
170 Nb96fb577d9f04e92b41d289e04afb942 rdf:first sg:person.01035671320.99
171 rdf:rest N9506ea2802cc4a89aaa1de0002d0f01d
172 Nc02dfece5e9e4089b4d474f4a3f0c8d9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Aged
174 rdf:type schema:DefinedTerm
175 Nc83257e201194669b0ae12a96dd6cf6e rdf:first sg:person.0761732367.29
176 rdf:rest Na4ffbd486ac64784982d9c4046d81eee
177 Ndc6fbce647f04bcfbb664dacd058755c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Receptors, Estrogen
179 rdf:type schema:DefinedTerm
180 Nec7bf1777ec648fba105324205d8ea58 schema:name pubmed_id
181 schema:value 29164421
182 rdf:type schema:PropertyValue
183 Nf83546db11984b31bf664bfd91f4b55c schema:name nlm_unique_id
184 schema:value 8111104
185 rdf:type schema:PropertyValue
186 Nfc2aaf2c54714d779f2a8a101fc18050 rdf:first sg:person.0774357225.44
187 rdf:rest N09af62adb7ea44469dced71c2c904d17
188 Nfcc6cbb5cd1e4d7dbd9505becb7273c1 rdf:first sg:person.01304125215.33
189 rdf:rest N6426d588212a4061b210d78ddef9efd3
190 Nfe527efe4c344df7883057e65f981690 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Middle Aged
192 rdf:type schema:DefinedTerm
193 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
194 schema:name Medical and Health Sciences
195 rdf:type schema:DefinedTerm
196 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
197 schema:name Oncology and Carcinogenesis
198 rdf:type schema:DefinedTerm
199 sg:journal.1092777 schema:issn 0167-6806
200 1573-7217
201 schema:name Breast Cancer Research and Treatment
202 rdf:type schema:Periodical
203 sg:person.01000127754.79 schema:affiliation https://www.grid.ac/institutes/grid.419466.8
204 schema:familyName Petrakova
205 schema:givenName Katarina
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000127754.79
207 rdf:type schema:Person
208 sg:person.01024444431.61 schema:affiliation N005455949be846c18f7b57d1b5ed76c3
209 schema:familyName Hart
210 schema:givenName Lowell L.
211 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01024444431.61
212 rdf:type schema:Person
213 sg:person.01035671320.99 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
214 schema:familyName Souami
215 schema:givenName Farida
216 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01035671320.99
217 rdf:type schema:Person
218 sg:person.01215373156.15 schema:affiliation https://www.grid.ac/institutes/grid.4305.2
219 schema:familyName Cameron
220 schema:givenName David A.
221 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01215373156.15
222 rdf:type schema:Person
223 sg:person.01237201171.19 schema:affiliation https://www.grid.ac/institutes/grid.492893.d
224 schema:familyName Lindquist
225 schema:givenName Deborah
226 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01237201171.19
227 rdf:type schema:Person
228 sg:person.01304125215.33 schema:affiliation https://www.grid.ac/institutes/grid.492660.f
229 schema:familyName Beck
230 schema:givenName Joseph T.
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01304125215.33
232 rdf:type schema:Person
233 sg:person.013436233237.01 schema:affiliation https://www.grid.ac/institutes/grid.412807.8
234 schema:familyName Arteaga
235 schema:givenName Carlos L.
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013436233237.01
237 rdf:type schema:Person
238 sg:person.01365732165.24 schema:affiliation https://www.grid.ac/institutes/grid.240145.6
239 schema:familyName Hortobagyi
240 schema:givenName Gabriel N.
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365732165.24
242 rdf:type schema:Person
243 sg:person.0612217745.26 schema:affiliation https://www.grid.ac/institutes/grid.477898.d
244 schema:familyName O’Shaughnessy
245 schema:givenName Joyce
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0612217745.26
247 rdf:type schema:Person
248 sg:person.0632337317.47 schema:affiliation https://www.grid.ac/institutes/grid.459623.f
249 schema:familyName Jakobsen
250 schema:givenName Erik
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632337317.47
252 rdf:type schema:Person
253 sg:person.0646473315.72 schema:affiliation https://www.grid.ac/institutes/grid.414603.4
254 schema:familyName Conte
255 schema:givenName Pierfranco
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0646473315.72
257 rdf:type schema:Person
258 sg:person.07527031577.24 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
259 schema:familyName Mondal
260 schema:givenName Shoubhik
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07527031577.24
262 rdf:type schema:Person
263 sg:person.0756327401.00 schema:affiliation https://www.grid.ac/institutes/grid.411158.8
264 schema:familyName Villanueva
265 schema:givenName Cristian
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756327401.00
267 rdf:type schema:Person
268 sg:person.0761732367.29 schema:affiliation https://www.grid.ac/institutes/grid.430814.a
269 schema:familyName Sonke
270 schema:givenName Gabe S.
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0761732367.29
272 rdf:type schema:Person
273 sg:person.0774357225.44 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
274 schema:familyName Germa
275 schema:givenName Caroline
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0774357225.44
277 rdf:type schema:Person
278 sg:pub.10.1007/s10549-014-2916-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017207411
279 https://doi.org/10.1007/s10549-014-2916-8
280 rdf:type schema:CreativeWork
281 sg:pub.10.1038/bjc.2015.127 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050007381
282 https://doi.org/10.1038/bjc.2015.127
283 rdf:type schema:CreativeWork
284 sg:pub.10.1038/nature11412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024942368
285 https://doi.org/10.1038/nature11412
286 rdf:type schema:CreativeWork
287 sg:pub.10.1038/nrd4504 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021914398
288 https://doi.org/10.1038/nrd4504
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1016/j.breast.2016.05.015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042721440
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1016/j.breast.2016.10.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046767167
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1016/j.ejca.2008.10.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026558254
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1016/s0140-6736(16)32389-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014303949
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1016/s0959-8049(16)32619-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010989294
299 rdf:type schema:CreativeWork
300 https://doi.org/10.1016/s1470-2045(15)00613-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025211268
301 rdf:type schema:CreativeWork
302 https://doi.org/10.1056/nejmoa1607303 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005496514
303 rdf:type schema:CreativeWork
304 https://doi.org/10.1056/nejmoa1609709 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045557388
305 rdf:type schema:CreativeWork
306 https://doi.org/10.1093/annonc/mdq220 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037043739
307 rdf:type schema:CreativeWork
308 https://doi.org/10.1093/annonc/mdw435.05 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083560034
309 rdf:type schema:CreativeWork
310 https://doi.org/10.1093/annonc/mdw544 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083734065
311 rdf:type schema:CreativeWork
312 https://doi.org/10.1093/annonc/mdx447 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092559985
313 rdf:type schema:CreativeWork
314 https://doi.org/10.1158/1535-7163.targ-13-pr02 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063229039
315 rdf:type schema:CreativeWork
316 https://doi.org/10.1200/jco.2016.67.1487 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010471013
317 rdf:type schema:CreativeWork
318 https://doi.org/10.1200/jco.2017.73.7585 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085860547
319 rdf:type schema:CreativeWork
320 https://doi.org/10.1371/journal.pone.0093755 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038929656
321 rdf:type schema:CreativeWork
322 https://doi.org/10.1530/erc-10-0262 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031547310
323 rdf:type schema:CreativeWork
324 https://doi.org/10.2147/pgpm.s52762 schema:sameAs https://app.dimensions.ai/details/publication/pub.1044821228
325 rdf:type schema:CreativeWork
326 https://doi.org/10.3322/caac.21254 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011682275
327 rdf:type schema:CreativeWork
328 https://www.grid.ac/institutes/grid.240145.6 schema:alternateName The University of Texas MD Anderson Cancer Center
329 schema:name University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030, Houston, TX, USA
330 rdf:type schema:Organization
331 https://www.grid.ac/institutes/grid.411158.8 schema:alternateName Centre Hospitalier Universitaire de Besançon
332 schema:name University Hospital of Besançon, Jean-Minjoz University Hospital, 3 Boulevard Alexandre Fleming, 25000, Besançon, France
333 rdf:type schema:Organization
334 https://www.grid.ac/institutes/grid.412807.8 schema:alternateName Vanderbilt University Medical Center
335 schema:name Vanderbilt-Ingram Cancer Center, 1301 Medical Center Dr #1710, 37232, Nashville, TN, USA
336 rdf:type schema:Organization
337 https://www.grid.ac/institutes/grid.414603.4 schema:alternateName Istituti di Ricovero e Cura a Carattere Scientifico
338 schema:name University of Padova and Istituto Oncologico Veneto, IRCCS, Via Gattamelata, 64, Padua, Italy
339 rdf:type schema:Organization
340 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
341 schema:name Novartis Pharmaceuticals Corporation, 1 Health Plaza, 07936, East Hanover, NJ, USA
342 rdf:type schema:Organization
343 https://www.grid.ac/institutes/grid.419466.8 schema:alternateName Masaryk Memorial Cancer Institute
344 schema:name Masaryk Memorial Cancer Institute, Žlutý kopec 543/7, 656 53, Brno, Czech Republic
345 rdf:type schema:Organization
346 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
347 schema:name Novartis Pharma AG, Fabrikstrasse 2, 4056, Basel, Switzerland
348 rdf:type schema:Organization
349 https://www.grid.ac/institutes/grid.4305.2 schema:alternateName University of Edinburgh
350 schema:name Edinburgh Cancer Centre, University of Edinburgh, Crewe Rd S, EH4 2XR, Edinburgh, UK
351 rdf:type schema:Organization
352 https://www.grid.ac/institutes/grid.430814.a schema:alternateName Antoni van Leeuwenhoek Hospital
353 schema:name Netherlands Cancer Institute and BOOG Study Center, IJsbaanpad 9, 1076 CV, Amsterdam, The Netherlands
354 rdf:type schema:Organization
355 https://www.grid.ac/institutes/grid.459623.f schema:alternateName Sygehus Lillebælt
356 schema:name Lillebaelt Hospital, Kabbeltoft 25, 7100, Vejle, Denmark
357 rdf:type schema:Organization
358 https://www.grid.ac/institutes/grid.477898.d schema:alternateName Texas Oncology
359 schema:name Texas Oncology-Baylor Charles A. Sammons Cancer Center and US Oncology Network, 3410 Worth Street, Suite 400, 75246, Dallas, TX, USA
360 rdf:type schema:Organization
361 https://www.grid.ac/institutes/grid.492660.f schema:alternateName Highlands Oncology Group
362 schema:name Highlands Oncology Group, 3232 N Northhills Blvd, 72703, Fayetteville, AR, USA
363 rdf:type schema:Organization
364 https://www.grid.ac/institutes/grid.492893.d schema:alternateName Arizona Oncology
365 schema:name Arizona Oncology, US Oncology Network, 3700 W State Rte 89A, 86336, Sedona, AZ, USA
366 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...